Australia, May 26 -- CRISPR Therapeutics AG, owns the trademark (2635973) for 'SYNTASE' till March 16, 2036.
Status: registered:
Registered/protected
Classes: 42 [Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of in vivo gene editing therapy; gene editing, namely, pharmaceutical research and development in the field of in vivo gene editing therapy; Research in the field of gene editing technology; Providing a gene editing platform for others to conduct pharmaceutical research and development in the field of in vivo gene editing therapy] and 42 [All items in this class are claimed in the convention application.]
Type of Mark: Word
Date of Acceptance: March 18
Regist...